Alcidion Group (ALC) Fair Value & Analysis
Healthcare · AU · Market cap A$148M
Fair value as of: Jun 26, 2026
From 24 valuation models · updated 3 days ago
Fair value updated Jun 26, 2026 — revised from A$0.0800 to A$0.0523 (−34.7%) since Jun 24, 2026. Share price −12.7% over the past month.
Price vs Fair Value (12 months)
12‑month range A$0.0871 – A$0.1385 · fair‑value band A$0.0428 – A$0.0523 · the A$0.0950 price screens above the A$0.0523 fair value. As of Jun 26, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Alcidion Group (ALC) currently trades at A$0.0950, while our model-based Fair Value estimate is A$0.0523 — implying the stock looks roughly 45.0% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Alcidion Group generated revenue of A$48.6M at a net margin of 8.0%. Revenue grew 44.4% year over year. It earns a return on equity of 4.4%. The balance sheet holds a net cash position of A$16.3M. Fundamentals as of Jun 26, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.
About the company
Alcidion Group Limited, together with its subsidiaries, engages in the development and licensing of healthcare software products in Australia, New Zealand, and the United Kingdom. It offers Miya Precision, a fast healthcare interoperability resource (FHIR)-events platform that integrates digital patient care services, such as a clinical decision support system, electronic patient record (EPR), and patient administration systems (PAS). The company platform also provides electronic patient flow journey boards; virtual care and remote patient management; integrated care system smart operations center; emergency department and specialized care; real-time data integration, FHIR-based interoperability, and predictive analytics; modern modular EPR; and streamlined clinical workflows, intelligent comms, and mobility solutions. In addition, the company offers Smartpage, a smartphone and web-based system for hospital communication and task management; and product implementation, product suppo…
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Alcidion Group reported revenue of A$40.8M in FY2025 versus A$25.9M in FY2021, a compound +12.0%/yr. Reported net income was A$1.7M in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Health Information Services stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Veeva Systems Inc VEEV | $153.16 | $183.66 | +20% |
| Pro Medicus Limited PME | A$172.80 | A$32.25 | -81% |
| BrightSpring Health Services, Inc BTSG | $60.59 | $23.87 | -61% |
| Tempus AI, Inc TEM | $48.61 | $12.67 | -74% |
| HealthEquity, Inc HQY | $84.61 | $79.57 | -6% |
| M3, Inc MTHRY | $5.03 | $7.44 | +48% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Alcidion Group (ALC) undervalued?
What is the fair value of ALC?
What is the quality score of ALC?
What is the revenue of Alcidion Group (ALC)?
What is the net profit margin of ALC?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.